Talimogene Laherparepvec in Treating Patients With Non-Muscle Invasive Bladder Transitional Cell Carcinoma
Last updated on July 2021Recruitment
- Recruitment Status
- Withdrawn
- Estimated Enrollment
- 30
Summary
- Conditions
- Stage 0 Bladder Urothelial Carcinoma AJCC v6 and v7
- Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7
- Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7
- Stage I Bladder Urothelial Carcinoma AJCC v6 and v7
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03430687
- Collaborators
- Amgen
- Investigators
- Principal Investigator: Terence Friedlander University of California, San Francisco
Get Well Soon